Discontinued Product

Piroxicam (Cat. No. 0960) has been withdrawn from sale for commercial reasons.
Description: Cyclooxygenase-1 (COX-1) inhibitor
Chemical Name: 3,4-Dihydro-2-methyl-4-oxo-N-2-pyridyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide
Purity: ≥99% (HPLC)
Literature (6)

Biological Activity for Piroxicam

Piroxicam is an anti-inflammatory; highly selective inhibitor of COX-1 (ratio of IC50 values for COX-2/COX-1 ~ 600).

Technical Data for Piroxicam

M. Wt 331.35
Formula C15H13N3O4S
Storage Store at RT
Purity ≥99% (HPLC)
CAS Number 36322-90-4
PubChem ID 54676228
Smiles CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=C(C=CC=C2)S1(=O)=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for Piroxicam

Certificate of Analysis / Product Datasheet
Select another batch:

References for Piroxicam

References are publications that support the biological activity of the product.

Mitchell et al (1995) Cyclooxygenase-2. Regulation and relevance in inflammation. Biochem.Pharmacol. 50 1535 PMID: 7503754

Merck Index 12 7661

View Related Products by Target

View Related Products by Product Action

View all Cyclooxygenase Inhibitors

Keywords: Piroxicam, Piroxicam supplier, Cyclooxygenase, COX-1, inhibitors, inhibits, COX, Oxygenases, Oxidases, 0960, Tocris Bioscience

Citations for Piroxicam

Citations are publications that use Tocris products.

Currently there are no citations for Piroxicam.

Reviews for Piroxicam

There are currently no reviews for this product. Be the first to review Piroxicam and earn rewards!

Have you used Piroxicam?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Cancer Research Product Guide

Cancer Research Product Guide

A collection of over 750 products for cancer research, the guide includes research tools for the study of:

  • Cancer Metabolism
  • Epigenetics in Cancer
  • Receptor Signaling
  • Cell Cycle and DNA Damage Repair
  • Angiogenesis
  • Invasion and Metastasis
Immunology Product Listing

Immunology Product Listing

A collection of over 190 products for immunology research, the guide includes research tools for the study of:

  • Chemokine and Cytokine Signaling
  • Chemotaxis
  • Complement System
  • Immune Cell Signaling
  • Inflammation
Pain Research Product Guide

Pain Research Product Guide

A collection of over 280 products for pain research, the guide includes research tools for the study of:

  • Nociception
  • Ion Channels
  • G-Protein-Coupled Receptors
  • Intracellular Signaling
Alzheimer's Poster

Alzheimer's Poster

Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.

Epilepsy Poster

Epilepsy Poster

Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.

Parkinson's Poster

Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.